Pharmaceutical composition for prevention or treatment of flavivirus infection
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12295967-B2
Publication Date
2025-05-13
Expiration Date
Abstract
A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.
Core Innovation
The invention relates to a pharmaceutical composition for preventing or treating flavivirus infection by administering to a subject a composition comprising specified repurposed compounds, including at least one of paromomycin, capreomycin, thioridazine HCl, miltefosine, resminostat, nedaplatin and cephalothin, or at least one of pharmaceutically acceptable salts of the above compounds. The described scope covers flavivirus infection in general and includes refinement to infections derived from dengue virus.
A problem addressed is the prevention or treatment of flavivirus infection, supported by a rationale that many administered agents inhibit conserved flaviviral replication enzymes, including RNA-dependent RNA polymerase (RdRp) and helicase. The document emphasizes that targeting conserved replication functions of flaviviruses supports broad activity across flavivirus species, with specific emphasis described for dengue, including dengue serotype 2.
The summary further reports that the approach shows flaviviral enzyme inhibition and reduced dengue viral outcomes in experimental settings. Reported results include reduced dengue viremia in AG129 mice, reduced dengue viral focal formation in VeroE6 cells, and improved survival/weight outcomes with montelukast, together with tissue-specific reductions in viral RNA and histology consistent with decreased viral replication.
Claims Coverage
The provided independent claims cover two main treatment/antiviral functions: treating a flavivirus infection and inhibiting growth of a flavivirus or killing the same. Across the independent claims, the inventive features are concentrated on administering a composition containing specified therapeutic agents, optionally further limited to particular flaviviruses including dengue virus.
Treating a flavivirus infection with a defined repurposed-drug composition
Administering to a subject in need thereof a composition comprising at least one of paromomycin, capreomycin, thioridazine HCl, miltefosine, resminostat, nedaplatin and cephalothin, or at least one of pharmaceutically acceptable salts of the above compounds.
Inhibiting growth or killing flavivirus with a defined repurposed-drug composition
Administering to a subject in need thereof a composition comprising at least one of paromomycin, capreomycin, thioridazine HCl, miltefosine, resminostat, nedaplatin and cephalothin, and at least one of pharmaceutically acceptable salts of the above compounds.
The independent claims define a composition-based approach for treating a flavivirus infection and inhibiting growth or killing flavivirus, centered on administering at least one of the specified compounds and/or their pharmaceutically acceptable salts. Dependent claims further narrow by specifying flavivirus targets including dengue virus and by identifying additional named therapeutic agents as present in the composition.
Stated Advantages
Inhibits conserved flaviviral replication enzymes, including RNA-dependent RNA polymerase (RdRp) and helicase.
Reduces dengue viremia in AG129 mice.
Reduces dengue viral focal formation in VeroE6 cells.
Provides improved survival/weight outcomes, reported with montelukast.
Produces tissue-specific reductions in viral RNA and histology consistent with decreased viral replication.
Documented Applications
Prevention or treatment of flavivirus infection, including refinement to dengue virus-derived infection.
Inhibition of flavivirus growth or killing of flavivirus.
Interested in licensing this patent?